Alexion expands Irish facility

A total of 400 direct and indirect jobs are being created by US niche drug firm, Alexion Pharmaceuticals as part of its second major Irish-based expansion announcement in as many months.

Alexion expands Irish facility

The Connecticut-headquartered firm — which works on treatments for people carrying ultra-rare and life-threatening disorders — yesterday announced the creation, within the next two years, of 200 full-time jobs via the building of its third facility here; a new €75m global supply chain facility at Blanchardstown, west Dublin.

Another 200 jobs are to be indirectly created through the construction of the new facility, which is due to open in 2016/17.

Alexion already employs more than 60 people at a site in Park West, in Dublin. In February, the company announced plans to build another facility in Athlone. Stretching over the three facilities, Alexion will employ around 300 people in Ireland within the next two years or so.

In Dublin for his company’s announcement, Alexion chief executive Leonard Bell said the moves cement management’s commitment to Ireland “as a key location” for the company’s global supply chain operations.

“Our choice of Ireland reflects the calibre of the workforce and the country’s culture of innovation. We look forward to an ongoing partnership with the Government, IDA Ireland and local communities in the years to come,” he added.

Alexion was recently recognised by Forbes Magazine, in the US, as the world’s second most innovative business; something noted by An Taoiseach Enda Kenny at yesterday’s announcement, when stressing the significance of such a vote of confidence in the country on behalf of another big multinational.

Similarly, the significance of the announcement wasn’t lost on IDA Ireland chief Barry O’Leary, who said training programmes — such as those provided by the National Institute for Bioprocessing Research and Training — have helped provide a skilful workforce for incoming companies.

“Alexion is one of the world’s leading biopharmaceutical companies. Their choice of Ireland as a location for their business is an endorsement of the strong infrastructure we have available for pharma companies,” Mr O’Leary said.

More in this section

IE logo
Devices


UNLIMITED ACCESS TO THE IRISH EXAMINER FOR TEAMS AND ORGANISATIONS
FIND OUT MORE

The Business Hub
Newsletter

News and analysis on business, money and jobs from Munster and beyond by our expert team of business writers.

Sign up
Lunchtime
News Wrap

A lunchtime summary of content highlights on the Irish Examiner website. Delivered at 1pm each day.

Sign up
Revoiced
Newsletter

Some of the best bits from irishexaminer.com direct to your inbox every Monday.

Sign up
Execution Time: 0.214 s